Accelerated timeline to manufacturer innovative CRISPR genetic editing treatment in six months' time
In a medical breakthrough, a six-month-old boy named Kyle Patrick Muldoon Jr., or KJ, has been saved from a rare and fatal metabolic disorder thanks to a pioneering CRISPR-Cas9 treatment. This personalised therapy, developed to correct a single-letter genetic mutation causing carbamoyl phosphate synthetase 1 (CPS1) deficiency, marks the first case of CRISPR base editing treatment for a lethal liver disorder.
KJ, who was diagnosed with the condition at birth, had no viable treatment options beyond a risky liver transplant. However, the new treatment, administered in February 2025, has proved to be a lifesaver. The therapy, published in the New England Journal of Medicine, was built on base editing technology developed in David Liu's lab.
The treatment works by precisely correcting the mutation at the DNA base level, restoring the liver's function to eliminate ammonia, a crucial step for survival. The genetic changes causing KJ's condition were two "misspellings" in his genetic code, one from each parent. The treatment was able to correct KJ's unique genetic mutation directly in his liver cells, allowing his body to absorb protein properly.
The team, led by a group of scientists and clinicians, compressed the full cycle-mutation discovery, design, validation, toxicology, and regulatory approval into a remarkable six months for KJ's treatment. The treatment consisted of an "editor" protein that performs the genetic modification and a guide RNA that acts like a GPS, pointing the editor to the precise location in the genome.
The final batch of the therapy was tested in liver cells in a dish to ensure it corrected KJ's genetic change and made no other significant changes. The team also had to demonstrate the therapy's safety even at high doses in monkeys. The treatment was delivered to KJ using lipid nanoparticles.
KJ's high ammonia levels were life-threatening, and he was put on dialysis and a low-protein diet. After receiving the treatment, his condition began to improve, and he was able to leave the hospital and return home with his family for the first time. This milestone marks a turning point in his recovery.
The CRISPR-Cas9 technology, which earned Jennifer Doudna and Emmanuelle Charpentier the 2020 Nobel Prize in Chemistry, has reshaped biotechnology and is now used to treat cancer, genetic disorders, and infectious diseases. This breakthrough in precision medicine, diagnostics, and synthetic biology is a significant step forward in the field of gene-editing interventions.
[1] Liu, D., et al. (2025). Base editing for a lethal liver disorder. New England Journal of Medicine. doi: 10.1056/NEJMoa2509962.
- The lifesaving treatment for KJ's rare and fatal metabolic disorder was a result of advancements in technology, specifically the field of robotics and science-driven innovation.
- The therapy, based on base editing technology developed by David Liu, has the potential to transform the treatment of chronic diseases like cancers and genetic disorders.
- Health-and-wellness and fitness-and-exercise could potentially benefit from this technological advancement as well, as the technology is now used to treat a variety of medical-conditions.
- The swift development of the CRISPR-Cas9 treatment for KJ's lethal liver disorder showcases the rapid progress being made in precision medicine, diagnostics, and synthetic biology.
- The use of CRISPR-Cas9 technology, which earned Jennifer Doudna and Emmanuelle Charpentier the 2020 Nobel Prize in Chemistry, has reshaped the landscape of biotechnology, offering new hope for those battling various medical-conditions.
